Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Andrew has over 5 years of professional experience working in Legal and Compliance. Andrew completed his studies at the University of Technology, Sydney earning a Bachelor of Law & Medical Science.

After graduating, Andrew took up a Compliance role at Novartis Pharmaceuticals Australia and New Zealand for 3 years before accepting a role at Sanofi ANZ in 2014 as the Country Compliance Officer. Andrew is responsible for managing the overall Compliance program including implementing effective SOPs and policies, conducting internal testing/monitoring and providing strategic compliance advice to the business units.

In 2015, Andrew received his Healthcare Compliance Certification from INSEAD, one of the top business schools in Europe. Andrew highly enjoys working on Compliance projects and finds it extremely rewarding partnering with the business units.

Katsumi KOJIMA is a Corporate officer, Country Compliance officer Japan of Sanofi Group, based in Tokyo, Japan. He is a member of the Code Compliance Committee, the Japanese Pharmaceutical Manufacturers Association (JPMA) and a member of the International Federation of Pharmaceutical Manufacturers and associations (IFPMA) Code Compliance Network.

He has been working for compliance field in the pharmaceutical and medical device industries over ten (10) years. He engaged in a speaker and a panellist on compliance topics in various conferences, such as "How Do I Know It's Working? Key Performance Indicators, Metrics and More" at Asia-Pacific Economic Cooperation (Nanjing, China) in 2014, "Venues & Locations of Third Party Conferences: What is Appropriate" at Advanced Medical Technology Association and Medical Technology Association of Australia Compliance Conference (Singapore) in 2014 and "Australia and Japan transparency updates" at the Global MedTech Compliance Conference (Barcelona, Spain) in 2014.

He earned LLB from Waseda University (Tokyo, Japan) and LLM from Hitotsubashi University (Tokyo, Japan). In addition, he received certification from INSEAD Compliance Implementation Leadership 1 (Fontainebleau, France) and Seton Hall Law School Aisa-Pacific Healthcare Compliance (Singapore). Since 2010, he has served as a Visiting Lecturer at Kyoto Prefectural University of Medicine (Kyoto, Japan).

Cristopher Landrito is the Area Compliance Officer of Takeda Pharmaceuticals in Asia Pacific, based in Singapore. He is a qualified lawyer from the Philippines with experience in litigation, banking, tax, and in government regulatory matters, in addition to ethics and compliance. He has worked in various capacities in the banking, pharmaceutical and chemicals industries, as well as in the legislature. Before assuming his current role, Cris was the Regional Compliance Officer of the Merck KGaA Group in Asia Pacific, and, previously, its Legal Counsel for its ethical pharma division in Southeast Asia.

Aaron is the compliance manager of Cordis (Shanghai) Medical Devices Co., Ltd. Before that, he was the compliance manager of Shanghai Roche Pharmaceutical Co., Ltd. His work mainly focus on compliance training, fraud investigation etc.

He has been awarded "Best Compliance Business Partner" by both Roche and Cordis and has rich compliance experience in how to collaborate well with business under Chinese compliance environment. Also, he has designed several compliance related training workshops during past years which has been warmly welcomed by business.

Keith Korenchuk is a partner in the FDA and Healthcare practice of Arnold & Porter, LLP in Washington D.C. He counsels and advises pharmaceutical, life sciences, medical device, biotechnology, and specialty pharmacy companies in the United States and worldwide on regulatory and compliance matters, including on the following matters:

• US and global compliance systems design, implementation, and ongoing assessment
• Regulatory matters involving healthcare professionals, including fraud and abuse, off-label promotion, False Claims Act and transparency related issues
• Global anti-bribery legislation, including the US Foreign Corrupt Practices Act, the Organization for Economic Co-operation and Development (OECD) Anti-bribery Convention, and related national implementing legislation
• Internal and government initiated investigations
• State legislation involving pharmaceutical and medical device marketing and disclosure
• Global, regional, and country specific codes of practice and conduct, including codes issues by Pharmaceutical Research and Manufacturers of America (PhRMA), AdvaMed, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and Eucomed
• Enterprise-wide risk management systems and programs
• Pharmaceutical price reporting and third party/managed markets negotiations

Michael Dusseau is a Vice President in the Global Compliance Organization of Actavis and responsible for the Global Compliance Operations function.

Michael has held senior leadership roles in the Compliance Organizations of Schering-Plough, Merck, Bayer and Actavis with broad responsibilities including the negotiation, implementation and operation of Corporate Integrity Agreements, global compliance training, global privacy program, monitoring, transparency, hotlines and compliance investigations. Michael has experience in both the Rx and Consumer segments of the business as well as in the design and implementation of compliance organizations and programs.

Michael has over 30 years of experience in the pharmaceutical industry and has held a variety of positions in sales, sales operations, information technology and compliance.

Michael holds a bachelor's degree in science from California State University, Long Beach.

Albert van Maaren is Regional Compliance Officer for APAC (including China and Japan) for Merck KGaA. Albert has over 20 years of experience in the pharmaceutical field, including regulatory affairs, pharmacovigilance, quality assurance, market access, compliance and as Pharmaceutical Affairs Director of the Netherlands and Belgium.

Prior to his role in Singapore, Albert was also dedicated compliance officer for the Benelux countries and Portugal. Albert graduated with a Pharmaceutical degree from Utrecht University, the Netherlands, and completed his Executive Master of Compliance at VU University in Amsterdam.

Chae Sing Wong has over 20 years of risk management, internal audit and compliance. His experience includes risk consulting and compliance roles in local, regional and global areas. He is currently the Compliance Director, APAC, MEA and LATM at Mundipharma. Prior to joining Mundipharma, he was Compliance Director of Asia, ANZ and Japan at Shire, and the Asia Compliance Director of AstraZeneca. In AstraZeneca, Chae Sing rolled out various compliance initiatives and programs such as data analytics, control self-assessment, and distributors' assurance review in order to transform the organization's culture, to strengthen assurance and simplified compliance processes and systems. He was also a member of the global compliance risk assessment taskforce for review and structure of the compliance model.

Chae Sing graduated with a degree in Accounting from the University of Malaya and is a Chartered Accountant, and he had previously served on the Global Board of Directors of the Professional Risk Managers' International Association (PRMIA). He speaks fluent Chinese, English and Malay.

Chi is a Forensic Technology Partner with EY's Fraud Investigation & Dispute Services practice in Shanghai. Chi has more than 14 years of experience in financial and enterprise data analytics and has worked in the United States, Australia and Greater China. He has extensive experience utilizing analytical software packages to join disparate data sets into a single repository, performing various analyses upon them, and identifying trends, patterns and outliers to detect fraud. Chi has led the design of a number of complex analytical engines leveraging predictive analysis, statistical modeling, data visualization, and text mining to help clients build continuous monitoring systems to identify fraudulent or high risk transactions timely and efficiently. He is also experienced in providing clients leading forensic data analytics solutions, including AML analytics, anti-bribery and anti-corruption analytics, Fraud Triangle analytics, third-party due diligence, business intelligence, text mining, and statistical anomaly detection. Chi has a Bachelor's Degree in Information Science from Peking University and a Master's Degree in Computer Science from Suffolk University. He is a Certified Fraud Examiner (CFE) and a Certified Information Systems Auditor (CISA).

Masood Ahmed is the Vice President and Regional Compliance Officer, Asia & JPAC of Sanofi Group.

Masood started his career as finance professional with Beecham. He had held positions of CFO in Upjohn, Pharmacia, GSK & vice President Operations Pfizer before embarking on his role as Regional Compliance Officer with Schering-Plough.

Masood had significantly contributed in several merger and integration activities of giant pharmaceutical organizations which provided him unique opportunities of managing people, strategies and processes integration and shaping the corporate culture.

Masood has been intimately involved in the evolution of Pharmaceuticals industry's compliance environment in challenging markets in Asia.

Gareth Lee is Vice President, Legal & Compliance, Asia Pacific at Cardinal Health. In this role, he heads Cardinal Health’s regional legal & compliance functions in markets around the Asia Pacific.

Gareth was previously Allergan’s General Counsel, Asia Pacific from 2009 till May 2015.

Gareth is a senior legal professional with 22 years experience. He started his legal career as a solicitor in the corporate & commercial practice with a leading Singapore law firm and thereafter as legal counsel with increasing scope & responsibilities in companies such as Royal Dutch Shell & Halliburton.

He has been in legal leadership positions in the pharmaceutical and medical devices industry for the past 11 years, including Baxter, Allergan and now, Cardinal Health.

Maria Eugenia (Maru) Quindimil is currently APAC Ethics and Compliance lead for UCB.

Previously, Maru has been Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation advisory firm serving executives, boards, investors and advisors in diverse sectors, primarily in the Americas, Europe and Africa.

Maru, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award."

Throughout a career that has spanned 27 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region.

Accountable for driving Abbott's Regional Ethics and Compliance Program in Asia region across its hugely diversified businesses i.e. Nutritional Products, Diabetes Care, Medical Optics, Vascular, Diagnostics, Pharmaceuticals and Molecular. One goal in mind: Nurture a robust organisation wide mindset of Triple Lenses of Responsibilities Framework -- Ethics, Economics/Finance and the Law.

An accomplished International Ethics & Compliance professional with combined 18 years of proven track record from scaling up to sustaining the Compliance Program together with Global and Regional key stakeholders. Experienced leading complex Audits and Investigations that resulted in a more robust internal controls structure and FCPA/ Anti-Bribery Anti-Corruption detective and preventive measures being put in place.

An outstanding people manager whose leadership philosophy is having a clear vision, empowering, coaching and the right intervention.

A Harvard Business School trained and well regarded industry thought leader. Rhys is currently the co-chairperson for Asia Pharmaceutical Compliance Congress, faculty member of Seton Hall University's Asia-Pacific Healthcare Compliance Program, founding member of the Asia-Pacific Healthcare Compliance Industry Group and member of the Harvard Business School Healthcare Alumni Association.

Jean-Christophe Pointeau joined Sanofi China in April 2015 as General Manager of Pharm China.

Pointeau brings with him over 20 years of international pharmaceutical experience in sales, marketing, medical affairs and access. Before joining Sanofi, he held a series of positions at Bristol-Myers Squibb (BMS), most notably President of BMS China from 2011 to 2014. Pointeau started his career in Rhone-Poulenc Rorer UK back in 1992. He also worked for Pfizer from 1997 to 2000.

Jean-Christophe Pointeau holds a Master of Healthcare Business Management from Ecole Supérieure de Commerce de Paris (ESCP) and a Master of Pharmacology from Paris-Sud University, France. He is a French national and lives in Shanghai with his family.

Mr. Dante Beccaria has been Global Compliance Officer and Vice President of Sanofi since April 2012. Mr. Beccaria began his career in 1985 in the field of Financing & Treasury and bank relationships first at Shell Italy and then Alcatel Italy. He has over 20 years' experience within Sanofi, having covered both operational and Corporate responsibilities. In 1990, he joined the Sanofi Italian affiliate to implement a Treasury Platform, gathering all the Business activities in the country. Since 1992, he served as Controlling Director of the Italian Pharma affiliate. In 1997, he moved to Paris to take global responsibilities as Pharma Controller at Sanofi Corporate, then as Chief Financial Officer of the OTC & Generics Division. In 2001, he became Projects Director within the Mergers & Acquisitions Corporate department. In 2003, he joined the Corporate Internal Audit as Associate Vice President. He served as Vice President of Internal Audit after the acquisition of Aventis. He holds a Degree in Economics from the University of Pavia (Italy).

Sujata Dayal is the Chief Compliance Officer for a 3 billion dollar global medical device company. Responsible for development, implementation and oversight of global compliance program with a focus on healthcare compliance and anti-corruption, Attorney with general corporate transactional and FDA regulatory experience. Experienced in setting up global compliance programs, including conducting risk-assessments, policy and procedure writing, training, monitoring and promotional review. Areas of expertise include health care compliance, FCPA and regulatory law. Specialties: Compliance Programs, Anti-corruption, Contracts, Regulatory Law, Promotional Review, Fraud and Abuse, Privacy

Anne Nielsen is a Senior Vice President & Chief Compliance and Ethics Officer at Bristol-Myers Squibb Company (BMS), based in New York. She joined the BMS Law Department in 1998 and was initially based in Belgium and moved to New York in 2009. Anne received her undergraduate degree in political science and economics and her master's degree in political science from the University of Hawaii. She received her JD from Columbia Law School, and also has a master's degree in European law from the College of Bruges (Belgium). Anne clerked for the Hon. Burton R. Lifland (Bankruptcy Court for the Southern District of New York). She was an associate at the law firms of Murphy, Weir & Butler and Howard, Rice in San Francisco. She also was an associate and partner at Forrester, Norall & Sutton in Brussels, Belgium and a partner at White & Case (Brussels), which acquired Forrester, Norall & Sutton.

Caroline West was appointed Global Chief Compliance Officer for Olympus Corporation on April 1, 2016 leading a compliance program with professionals located in Japan, Asia, the Americas, Europe, the Middle East and Africa. She joined Olympus Corporation of the Americas in January 2016 as Chief Compliance Officer for the Americas. Prior to joining Olympus, she served over 10 years as Senior Vice President, Chief Compliance & Risk Officer for Shire Pharmaceuticals where was responsible for building and leading a global compliance program. Prior to Shire, Caroline spent nearly 5 years with Aventis (later Sanofi) as VP Global Legal Compliance. Earlier in her career, she spent time in various legal and compliance positions at Rhone Poulenc Rorer, UGI Corporation and Pepper Hamilton LLP, where she began her career as a litigation associate.

Ms. West has an AB from Smith College and a JD from Penn State - Dickinson Law. She and her husband live in Philadelphia, PA and have two adult children.

Ted is a senior executive with over 22 years of professional services experience. He began his career as a practicing white-collar and regulatory attorney both in private practice and with the US Federal government. He has spent the last 15 years at EY where he focused on assisting clients with internal investigations and compliance program structures for US regulatory obligations, as well as foreign standards. In that role, Ted served many public and private Fortune 500 companies on matters in over 50 countries, working significantly on the ground and with C-suites.

In 2014, Ted was named Vice Chair of Risk for EY's Americas and US firms and appointed to their management boards. He leads the Risk Management organization, which covers internal risk assessments, compliance, ethics, privacy and independence, as well enterprise risk management, and client and engagement acceptance, among others. Ted also chairs EY Americas' ethics board and sits on EY's Global Risk Management Executive Committee and the Global Practice Group. In addition, Ted continues to serve a select number of clients and is the Global Life Sciences Fraud Investigation & Dispute Services Leader.

Graeme works with governments and anti-corruption authorities in the Asia and Pacific regions to enhance anti-corruption measures, with a focus on combating international bribery. He leads anti-corruption initiatives in the region including in partnership with the G20 Anti-Corruption Working Group and through the ADB/OECD Anti-Corruption Initiative for Asia and the Pacific. Graeme also conducts regular monitoring of the implementation of the OECD Anti-Bribery Convention by the member countries of the Working Group on Bribery in International Business Transactions.

Prior to joining the OECD, Graeme worked on domestic and international anti-corruption matters as a senior lawyer at the Attorney-General's Department of Australia and also as a litigation lawyer in private legal practice. He has a Bachelor of Laws, Bachelor of Arts and a Master of International Affairs from the Australian National University.

Ben leads one of the two Bribery and Corruption Divisions, and is a member of the SFO's Management Board reporting to the Director, David Green CB QC.

Operationally, Ben is responsible for numerous multi-jurisdictional bribery and corruption investigations involving some of the largest global institutions. He has also played a close part in developing the legislation and guidance relating to the UK's new Deferred Prosecution Agreement regime, and is at the forefront of the UK's deployment of that new prosecutorial tool. Ben has a particular interest in the continued development of the law relating to corporate criminal liability, and the role corporates and banks can play in helping to create a thriving and morally sound commercial environment in the UK and internationally.

Ben joined the SFO in August 2013 having previously been a member of Norton Rose Fulbright LLP's Business Ethics and Anti-Corruption team. In that capacity, Ben acted for major British and multi-national entities in the financial services, natural resources, oil and gas and logistics sectors, helping to manage their response to corruption incidents either within their own organisations, or in their competitive environment.

Neill Stansbury is Co-founder and Director of the Global Infrastructure Anti-Corruption Centre (GIACC). He is a construction lawyer who has worked for over 30 years in the international infrastructure sector. He is Chairman of the International Organization for Standardization (ISO) Anti-Bribery Project Committee, Past Chairman of British Standards Institute Anti-Bribery Working Group, and Vice Chairman of the World Federation of Engineering Organisation's Anti-Corruption Standing Committee. He was independent anti-corruption compliance monitor of Balfour Beatty, Parsons Brinckerhoff and Mabey Bridge. He is co-author of the GIACC Resource Centre. He has given anti-corruption presentations and workshops in over 25 countries.

Sophie Peresson is the Director of Transparency International's Pharmaceuticals and Healthcare Programme (PHP). The Programme has been set up with a purpose to achieve genuine change in the pharmaceutical & healthcare sector through reducing corruption and promoting transparency, integrity and accountability.

Sophie holds a Masters in Law from the Sorbonne University, a post-graduate degree from the School of Advanced International Studies (SAIS) Johns Hopkins University. She is currently completing an MSc in Global Health at the London School of Hygiene and Tropical Medicine.

She has over fifteen years' experience of working in public health, working for influential international NGOs such as the Red Cross and Marie Stopes International. Her experience spans both communicable and non-communicable diseases. She is an expert adviser to the European Institute for Women's Health (EIWH) and has held several board positions. She is also a contributor to the Global Burden of Disease Study. She has a well-established track record in collaborating in international projects, research initiatives and has been on the steering committee of several influential publications, e.g. The Diabetes Policy Puzzle.